Infant Bacterial Therapeutics AB (publ)

SSE:IBT-B.ST

93.4 (SEK) • At close February 20, 2024
Bedrijfsnaam Infant Bacterial Therapeutics AB (publ)
Symbool IBT-B.ST
Munteenheid SEK
Prijs 93.4
Beurswaarde 1,215,890,540
Dividendpercentage 0%
52-weken bereik 41.3 - 106.5
Industrie Biotechnology
Sector Healthcare
CEO Mr. Staffan Stromberg Ph.D.
Website https://www.ibtherapeutics.com

An error occurred while fetching data.

Over Infant Bacterial Therapeutics AB (publ)

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for

Vergelijkbare Aandelen

SpectraCure AB (publ) logo

SpectraCure AB (publ)

SPEC.ST

2.605 SEK

Orexo AB (publ) logo

Orexo AB (publ)

ORX.ST

14.5 SEK

Physitrack PLC logo

Physitrack PLC

PTRK.ST

15.2 SEK

Integrum AB (publ) logo

Integrum AB (publ)

INTEG-B.ST

43.35 SEK

Boule Diagnostics AB (publ) logo

Boule Diagnostics AB (publ)

BOUL.ST

9.36 SEK

Karolinska Development AB (publ) logo

Karolinska Development AB (publ)

KDEV.ST

1.65 SEK

Enzymatica AB (publ) logo

Enzymatica AB (publ)

ENZY.ST

3.05 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)